ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Roche gets US FDA approval for Tecentriq combo to treat advanced melanoma
August 03, 2020The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf helped people live longer without disease worsening or death. -
Roche’s Tecentriq/Cotellic study fails in colorectal cancer trial
July 09, 2018Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC). -
TECENTRIQ, COTELLIC Did Not Meet Primary Endpoint
May 18, 2018Genentech announced the Phase III IMblaze370 study evaluating the combination of TECENTRIQ (atezolizumab) and COTELLIC (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib.
Pharma Sources Insight January 2025
